Convergen raised $15 million in Seed+ financing to advance its degrader platform and move lead therapies for neurodegenerative diseases toward clinical development.
- Amount
- $15M
- Stage
- Seed
- Announced
- 31 August 2026
- Lead
- MPCi
- Other investors
- LAV, BioTrack Capital
- Use of funds
- Further advance proprietary degrader platform and accelerate pipeline for neurodegenerative disorders and other protein aggregation diseases.
- Checked
- Announced by the company